Christopher Frankenfield's most recent trade in Xilio Therapeutics Inc was a trade of 668,789 Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 668,789 | 668,789 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 19,375 | 38,750 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 19,375 | 31,796 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.64 per share. | 31 Dec 2025 | 7,030 | 24,766 | - | 0.6 | 4,522 | Common Stock |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 925,000 | 925,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 300,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 155,090 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 155,090 | 155,090 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 150,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 117,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 117,000 | 117,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 37,296 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 37,296 | 37,296 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 23,786 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 23,786 | 23,786 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 251,000 | 251,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 19,375 | 19,375 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 19,375 | 58,125 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 01 Jan 2025 | 6,954 | 12,421 | - | 1.0 | 6,841 | Common stock |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2024 | 52,000 | 52,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 208,000 | 208,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Frankenfield Christopher | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 77,500 | 77,500 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |